These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8143220)

  • 1. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
    Dorian P; Newman D; Harris L; Downar E
    Can J Cardiol; 1994 Mar; 10(2):193-200. PubMed ID: 8143220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.
    Boriani G; Biffi M; Frabetti L; Maraschi M; Branzi A
    Heart Lung; 2000; 29(6):412-6. PubMed ID: 11080321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
    Naccarella F; Rolli A; Carboni A; Finardi A; Aurier E; Favaro L; Contini S; Gherli T; Caponi D; Maranga SS; Lepera G; Bartoletti A
    G Ital Cardiol; 1999 Oct; 29(10):1142-56. PubMed ID: 10546124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sotalol on ventricular fibrillation and defibrillation in humans.
    Dorian P; Newman D
    Am J Cardiol; 1993 Aug; 72(4):72A-79A. PubMed ID: 8346730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation.
    Leong-Sit P; Gula LJ; Diamantouros P; Krahn AD; Skanes AC; Yee R; Klein GJ
    Am Heart J; 2006 Dec; 152(6):1104-8. PubMed ID: 17161062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Swiatecka G
    Kardiol Pol; 2005 Apr; 62(4):317-28; discussion 329-31. PubMed ID: 15928737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable defibrillators and/or amiodarone: alternatives or complementary therapies.
    Dorian P; Newman D; Greene M
    Int J Clin Pract; 1998 Sep; 52(6):425-8. PubMed ID: 9894382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators.
    Kruger A; Aronow WS; Lai H; Desai H; Singla A; Frishman WH; Cohen M; Sorbera C
    Am J Ther; 2009; 16(4):323-5. PubMed ID: 19617719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy.
    Dorian P; Newman D; Sheahan R; Tang A; Green M; Mitchell J
    J Cardiovasc Electrophysiol; 1996 Oct; 7(10):952-61. PubMed ID: 8894937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
    Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
    Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of antiarrhythmic drugs in reducing the number of defibrillation shocks].
    Deharo JC; Mouliom F; Salamand A; Djiane P
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):140-4. PubMed ID: 15787306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.